Changes in Beneficial Ownership · 4
Wave Life Sciences, Inc.
WVENASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-10082026_011038.xml
Filing details
- Report period
- 2026-10-05
- Issuer
- Wave Life Sciences, Inc.
- Issuer CIK
- 0001631574
- Trading symbol
- WVE
Reporting owner 1
- Name
- RA CAPITAL MANAGEMENT, L.P.
- Reporting owner CIK
- 0001346824
- Relationship
- Director · 10% owner
- Address
- 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116
Reporting owner 2
- Name
- RA Capital Healthcare Fund LP
- Reporting owner CIK
- 0001315082
- Relationship
- Director · 10% owner
- Address
- 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116
Reporting owner 3
- Name
- Kolchinsky Peter
- Reporting owner CIK
- 0001384859
- Relationship
- Director · 10% owner
- Address
- C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116
Reporting owner 4
- Name
- Shah Rajeev M.
- Reporting owner CIK
- 0001619841
- Relationship
- Director · 10% owner
- Address
- C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-05 | A · Form 4 | 10,700[F1] | A | 0 | 39,515 | I | See footnotes[F2][F3] |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- I
- Indirect
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 26,975,505 | I | See footnotes[F3][F4] |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 3.75 | 2026-10-05 | A · Form 4 | 64,000 | A | 0 | [F5] | 2036-10-05 | Ordinary Shares | 64,000 | 64,000 | I | See Footnotes[F2][F3] |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- I
- Indirect
Footnotes
- F1
- Dr. Kolchinsky was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Issuer's 2027 annual meeting of stockholders or October 5, 2027.↩ 1
- F2
- Dr. Kolchinsky is a Managing Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Kolchinsky's arrangement with the Adviser, Dr. Kolchinsky holds the RSUs and options for the benefit of the Fund. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or shares received upon settlement of the RSUs, or exercise of the options, as applicable, which will offset advisory fees owed by the Fund to the Adviser.↩ 1↩ 2
- F3
- RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.↩ 1↩ 2↩ 3
- F4
- Held directly by the Fund.↩ 1
- F5
- Dr. Kolchinsky was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Issuer's 2027 annual meeting of stockholders or October 5, 2027.↩ 1
Remarks
Dr. Peter Kolchinsky, a Managing Partner of the Adviser, serves on the Issuer's board of directors.
Signature 1
- Signed
- /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
- Date
- 2026-10-07
Signature 2
- Signed
- /s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.
- Date
- 2026-10-07
Signature 3
- Signed
- /s/ Peter Kolchinsky, individually
- Date
- 2026-10-07
Signature 4
- Signed
- /s/ Rajeev Shah, individually
- Date
- 2026-10-07
Company context
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s lead pipeline programs include obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 I148M liver disease (WVE-008), as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Current securities
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security HoldersNov 18, 2026
- 10-Q filingOct 27, 2026
- Results of Operations and Financial ConditionOct 27, 2026
- ARS filingOct 14, 2026
- DEF 14A filingOct 14, 2026